№ files_lp_3_process_7_095213
File format: docx Character count: 15895 File size: 420 KB
Standard operating procedure describing in-vitro and ex-vivo laboratory assays for measuring the survival rate of Plasmodium falciparum parasites following controlled exposure to piperaquine.
Procedure ID: PSAv1.0
Version number: 1.0
Release date: 20 March 2017
Developed by: Benoit Witkowski & Didier Ménard
Institution: Unité d’Epidémiologie Moléculaire du Paludisme, Institut Pasteur du Cambodge
Location: Phnom Penh, Cambodia
Document type: Laboratory procedure
Purpose: Evaluation of Plasmodium falciparum susceptibility to piperaquine
Assay types: In-vitro Piperaquine Survival Assay (PSA); Ex-vivo Piperaquine Survival Assay
Target organism: Plasmodium falciparum
Drug tested: Piperaquine (PPQ)
Drug concentration: 200 nM
Exposure duration: 48 hours
Assessment time point: 72 hours after drug exposure
Intended users: Appropriately-equipped laboratories performing in-vitro and ex-vivo drug susceptibility testing
Quality requirements: Training required; participation in QA/QC proficiency scheme recommended
Referenced study: Duru et al. 2015
Contact information: [email protected]
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Safety Data Sheet: Human red cell reagents for in-vitro diagnostic use only
Year: 2023
Region / city: United Kingdom, Liverpool
Subject: Safety Data Sheet for human red cell reagents
Document type: Safety Data Sheet
Organization: NHSBT Reagents
Author: NHSBT Reagents
Target audience: Healthcare professionals, laboratory technicians
Period of validity: Not specified
Approval date: Not specified
Date of changes: Not specified
Do In-vitro dissolution rates differ between beclomethasone dipropionate particles generated from solution-based pMDIs formulated with HFA134a, HFA152a and HFO1234ze(E) propellants?
Year: 2023
Region / City: Sydney, Australia
Topic: Pharmaceutical Sciences, Aerosol Drug Delivery, Inhaler Technology
Document Type: Research Article
Organization / Institution: Woolcock Institute of Medical Research, Macquarie University, Monash University, Kindeva Drug Delivery
Author: Hui Xin Ong, Nirmal Marasini, Lingzhe Rao, Daniel Duke, Damon Honnery, Stephen W. Stein, Benjamin Myatt, Phil Cocks, Paul Young
Target Audience: Researchers, Pharmaceutical Scientists, Engineers in Drug Delivery
Effective Period: Not specified
Approval Date: Not specified
Modification Date: Not specified
In-vitro and In-Silico Evaluation of Antioxidant and Anti-Inflammatory Potential of Beta Vulgaris Ethanol Extract in H2O2 Induced Oxidative Stress in HepG2 Cells
Year: 2023
Region / City: Rivers State, Nigeria
Topic: Antioxidant, Anti-inflammatory, Molecular Docking, Hepatoprotective
Document Type: Research Article
Institution: Rivers State University
Author: Not specified
Target Audience: Researchers, Scholars, Pharmacologists
Period of Validity: Not specified
Approval Date: Not specified
Date of Revisions: Not specified
Instructions for Completing and Submitting Form 2_IDV for Registration of In-Vitro Diagnostic Medical Devices
Year: 2023
Country: Italy
Ministry: Ministry of Health (Ministero della Salute)
Department: Direzione Generale dei Dispositivi Medici e del Servizio Farmaceutico, Ufficio 4
Document Type: Instruction/Guideline
Legal Reference: Ministerial Decree 23 December 2013, Legislative Decree no. 332 of 8 September 2000, Regulation (EU) 2017/746
Target Audience: Delegating and authorised companies registering in-vitro diagnostic devices
Required Attachments: Proof of identity of legal representatives
Submission Method: PDF via email to [email protected]
Data Entry: Appointed responsible person for entering and updating data in “Repertorio”
Topics: Ex-Vivo Piperaquine in-vitro